Clinical Cancer Research CR Helping Patients Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trikha, M.
Right arrow Articles by Rossi, J.-F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trikha, M.
Right arrow Articles by Rossi, J.-F.
Related Collections
Right arrow Cancer Immunology
Right arrow Cancer Immunology: Antibodies
Clinical Cancer Research Vol. 9, 4653-4665, October 15, 2003
© 2003 American Association for Cancer Research

Perspectives

Targeted Anti-Interleukin-6 Monoclonal Antibody Therapy for Cancer

A Review of the Rationale and Clinical Evidence

Mohit Trikha1, Robert Corringham, Bernard Klein and Jean-François Rossi

Centocor, Malvern, Pennsylvania 19355 [M. T., R. C.], and Unit of Cellular Therapy and INSERM U475 [B. K.] and Service d’Hématologie et d’Oncologie Médicale and INSERM U475 [J-F. R.], Montpellier, France 34295

ABSTRACT

Interleukin (IL)-6, a pleiotropic cytokine with varied systemic functions, plays a major role in inflammatory processes. It modulates the transcription of several liver-specific genes during acute inflammatory states, particularly C-reactive protein, and controls the survival of normal plasmablastic cells. In addition, IL-6 has been implicated in hematopoiesis as a cofactor in stem cell amplification and differentiation. This article is the first review of clinical studies in the 1990s with anti-IL-6 monoclonal antibodies (mAbs) in the treatment of patients with cancer and related lymphoproliferative disorders. In six clinical studies of mAbs to IL-6 with BE-8 or CNTO 328 in patients with multiple myeloma, renal cell carcinoma, and B-lymphoproliferative disorders, anti-IL-6 mAb treatment decreased C-reactive protein levels in all patients. In most patients, levels decreased below detectable limits. The antibodies were well tolerated, and no serious adverse effects were observed in the vast majority of studies. The fact that anti-IL-6 mAb therapy decreased the incidence of cancer-related anorexia and cachexia may also be useful in the treatment of cancer patients.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
T. J. Stewart, D. J. Liewehr, S. M. Steinberg, K. M. Greeneltch, and S. I. Abrams
Modulating the Expression of IFN Regulatory Factor 8 Alters the Protumorigenic Behavior of CD11b+Gr-1+ Myeloid Cells
J. Immunol., July 1, 2009; 183(1): 117 - 128.
[Abstract] [Full Text] [PDF]

Home page
 BMJ Case ReportsHome page
A. Siniscalchi, R. Stasi, S. Fratoni, P. de Fabritiis, and T. Caravita
Management of immune thrombocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer
BMJ Case Reports, June 11, 2009; 2008(jun09_1): bcr0320091715 - bcr0320091715.
[Abstract] [Full Text]

Home page
 Anticancer ResHome page
J. MASHIAH, S. BRENNER, Y. PESSACH, V. BARAK, and J. SCHACHTER
Differences in Cytokine Levels in Melanoma Patients with and without Redness (Brenner Sign)
Anticancer Res, May 1, 2009; 29(5): 1793 - 1796.
[Abstract] [Full Text] [PDF]

Home page
 BMJ Case ReportsHome page
P. A Engel and C. Lee
Sudden appearance and spontaneous regression of diffuse large B cell lymphoma in a man with a broken arm
BMJ Case Reports, March 5, 2009; 2009(mar02_1): bcr1020081036 - bcr1020081036.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
R. J. Biggar, J. S. Johansen, K. E. Smedby, K. Rostgaard, E. T. Chang, H.-O. Adami, B. Glimelius, D. Molin, S. Hamilton-Dutoit, M. Melbye, et al.
Serum YKL-40 and Interleukin 6 Levels in Hodgkin Lymphoma
Clin. Cancer Res., November 1, 2008; 14(21): 6974 - 6978.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
B. B. Ancrile, K. M. O'Hayer, and C. M. Counter
Oncogenic Ras-Induced Expression of Cytokines: A New Target of Anti-Cancer Therapeutics
Mol. Interv., February 1, 2008; 8(1): 22 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. M. Richey, J. R. George, M. E. Couch, B. K. Kanapkey, X. Yin, T. Cannon, P. W. Stewart, M. C. Weissler, and C. G. Shores
Defining Cancer Cachexia in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., November 15, 2007; 13(22): 6561 - 6567.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Huynh, P. K.H. Chow, and K.-C. Soo
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
Mol. Cancer Ther., September 1, 2007; 6(9): 2468 - 2476.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
B. Ancrile, K.-H. Lim, and C. M. Counter
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
Genes & Dev., July 15, 2007; 21(14): 1714 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Younes, X. Leleu, E. Hatjiharissi, A.-S. Moreau, T. Hideshima, P. Richardson, K. C. Anderson, and I. M. Ghobrial
Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma
Clin. Cancer Res., July 1, 2007; 13(13): 3771 - 3775.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Chen, M. S. Gordon, R. A. Campbell, M. Li, C. S. Wang, H. J. Lee, E. Sanchez, S. J. Manyak, D. Gui, D. Shalitin, et al.
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth
Blood, July 1, 2007; 110(1): 287 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. A. Charles, L. P. Rivory, S. L. Brown, C. Liddle, S. J. Clarke, and G. R. Robertson
Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer
Clin. Cancer Res., December 15, 2006; 12(24): 7492 - 7497.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. Paschoud, A. M. Dogar, C. Kuntz, B. Grisoni-Neupert, L. Richman, and L. C. Kuhn
Destabilization of Interleukin-6 mRNA Requires a Putative RNA Stem-Loop Structure, an AU-Rich Element, and the RNA-Binding Protein AUF1
Mol. Cell. Biol., November 15, 2006; 26(22): 8228 - 8241.
[Abstract] [Full Text] [PDF]

Home page
 Biol Res NursHome page
L. J. Wood, L. M. Nail, N. A. Perrin, C. R. Elsea, A. Fischer, and B. J. Druker
The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior-like Symptoms in a Mouse Model of Cancer Chemotherapy-Related Symptoms.
Biol Res Nurs, October 1, 2006; 8(2): 157 - 169.
[Abstract] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
M. Maggio, J. M. Guralnik, D. L. Longo, and L. Ferrucci
Interleukin-6 in aging and chronic disease: a magnificent pathway.
J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 575 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. S. Johansen, B. V. Jensen, A. Roslind, D. Nielsen, and P. A. Price
Serum YKL-40, A New Prognostic Biomarker in Cancer Patients?
Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 194 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. L. Nowlan, E. Drewe, H. Bulsara, N. Esposito, R. A. Robins, P. J. Tighe, R. J. Powell, and I. Todd
Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A
Rheumatology, January 1, 2006; 45(1): 31 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Dalwadi, K. Krysan, N. Heuze-Vourc'h, M. Dohadwala, D. Elashoff, S. Sharma, N. Cacalano, A. Lichtenstein, and S. Dubinett
Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non-Small Cell Lung Cancer
Clin. Cancer Res., November 1, 2005; 11(21): 7674 - 7682.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Corpeleijn, W. H. M. Saris, E. H. J. M. Jansen, P. M. H. J. Roekaerts, E. J. M. Feskens, and E. E. Blaak
Postprandial Interleukin-6 Release from Skeletal Muscle in Men with Impaired Glucose Tolerance Can Be Reduced by Weight Loss
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5819 - 5824.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Coxon, E. Rozenblum, Y.-S. Park, N. Joshi, J. Tsurutani, P. A. Dennis, I. R. Kirsch, and F. J. Kaye
Mect1-Maml2 Fusion Oncogene Linked to the Aberrant Activation of Cyclic AMP/CREB Regulated Genes
Cancer Res., August 15, 2005; 65(16): 7137 - 7144.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Martignoni, P. Kunze, W. Hildebrandt, B. Kunzli, P. Berberat, T. Giese, O. Kloters, J. Hammer, M. W. Buchler, N. A. Giese, et al.
Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer-Related Cachexia
Clin. Cancer Res., August 15, 2005; 11(16): 5802 - 5808.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-L. Su, K.-P. Lai, C.-A. Chen, C.-Y. Yang, P.-S. Chen, C.-C. Chang, C.-H. Chou, C.-L. Hu, M.-L. Kuo, C.-Y. Hsieh, et al.
A Novel Peptide Specifically Binding to Interleukin-6 Receptor (gp80) Inhibits Angiogenesis and Tumor Growth
Cancer Res., June 1, 2005; 65(11): 4827 - 4835.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. H. Gordon, R. J. O'Keefe, E. M. Schwarz, R. N. Rosier, and J. E. Puzas
Nuclear Factor-{kappa}B-Dependent Mechanisms in Breast Cancer Cells Regulate Tumor Burden and Osteolysis in Bone
Cancer Res., April 15, 2005; 65(8): 3209 - 3217.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
D. E. Spaner
Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells
J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Mahtouk, M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, and B. Klein
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis
Blood, March 1, 2004; 103(5): 1829 - 1837.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.